<p><strong>Pediatric Use</strong>: Safety and effectiveness of Telmisartan and Hydrochlorothiazide in pediatric patients have not been established.<br />
<br />
<strong>Geriatric Use</strong>: In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function and of concomitant diseases or other drug therapy.<br />
<br />
<strong>Use in Patients with Hepatic Impairment</strong>: Patients with biliary obstructive disorders or hepatic insufficiency should initiate treatment under close medical supervision.<br />
<br />
<strong>Use in Patients with Renal Impairment</strong>: Safety and effectiveness of Telmisartan and Hydrochlorothiazide in patients with severe renal impairment (Cr.Cl. &lt;30 ml/min) have not been established. In patients with severe renal impairment, Telmisartan and Hydrochlorothiazide tablets are not recommended. No dose adjustment is required in patients with mild (Cr.Cl. 60 to 90 ml/min) or moderate (Cr.Cl. 30 to 60 ml/min) renal impairment.</p>